Commentary|Podcasts|June 26, 2023

Pharmacy Focus: Oncology Edition - A Look Into Psychedelic Medicines for Oncology Care

This month, we have a special crossover episode between Pharmacy Focus: Oncology Edition and the Psychedelic Pharmacy podcast.

This month, we have a special crossover episode between Pharmacy Focus: Oncology Edition and the Psychedelic Pharmacy podcast. Managing Editor Alana Hippensteele spoke with Anthony L. Back, MD, to learn about research into psychedelic medicine in cancer care and what he sees in the future. As psychedelic medicine comes further into cancer care, pharmacists will play a vital role in the interdisciplinary team to screen and evaluate patients for suitability.

Stay informed on drug updates, treatment guidelines, and pharmacy practice trends—subscribe to Pharmacy Times for weekly clinical insights.

Related to this article

September 21st, 2026

Target Trial Emulation Finds Limited Survival Benefit With Statins After Colorectal Cancer Treatment

Statin initiation after colorectal cancer treatment was associated with only modest survival differences after investigators accounted for biases that can exaggerate benefits in observational research.

Non–small cell lung cancer (NSCLC) -- Image credit: Dr_Microbe | stock.adobe.com

September 17th, 2026

FDA Grants Approval to sNDA for Taletrectinib in Advanced ROS1+ NSCLC

This update came with no changes to the safety sections of labeling, with no new signals identified with longer follow-up.

September 17th, 2026

FDA Reduces Monitoring Time for First Two Tarlatamab Doses

The update shortens required observation to 6 to 8 hours from 22 to 24, easing tarlatamab administration in community settings for ES-SCLC.

September 17th, 2026

Radioligand Therapy Doesn’t Need to Be Risk-Free—It Needs to Be Worth It

Thomas Hope, MD, explains why radioligand therapies should be evaluated according to whether their clinical benefits outweigh their risks within the context of patients’ available cancer treatment options.

September 16th, 2026

Trial Ended Early When Venetoclax Plus DA-EPOCH-R Did Not Improve Outcomes in Double-Hit Lymphoma

The randomized ALLIANCE A051701 trial closed early when treatment-related toxicity and mortality were increased without improving PFS in patients with newly diagnosed double-hit lymphoma.

September 16th, 2026

Bladder Cancer Treatment Is Advancing Faster Than Answers on Sequencing and Toxicity Management

Robin Tumlinson, PharmD, BCOP, discusses how rapidly expanding bladder cancer options are creating new questions around treatment sequencing, toxicity management, biomarker testing, and multidisciplinary care.

September 15th, 2026

Higher Pulmonary Microplastic Burden Observed in Patients With Lung Cancer

A prospective observational study found microplastics more frequently and at higher levels in lung samples from patients with lung malignancies, although the findings do not establish that the particles cause cancer.

September 15th, 2026

Study Links H. pylori Exposure to Greater Global Colorectal Cancer Burden

Helicobacter pylori exposure could be associated with approximately 22% of colorectal cancer cases worldwide.

Pharmacy Focus: Oncology Edition - A Look Into Psychedelic Medicines for Oncology Care

Related to this article

Trending on Pharmacy Times

Dapagliflozin in Heart Failure: Congestion Isn't the Gatekeeper

New Data Reshapes Nonstatin Lipid Therapy Choices

Ambulatory Pharmacists Convene in Boston at NEIAP's 2026 Annual Forum

Semaglutide Linked to Up to 40% Fewer Asthma Attacks, Real-World Data Show

Baseline Interferon Activity in Monocytes Predicts mRNA Vaccine Adverse Effects, Study Finds